This article is a commentary on AI regulation and does not report on any new developments, funding, product launches, or approvals.
This NICE recommendation opens up a significant new market for Astellas' Veoza within the UK's public healthcare system. It provides a non-hormonal treatment option for a large patient population, potentially capturing market share from existing hormonal therapies and establishing Veoza as a key treatment for menopause symptoms in the UK.
UK's NICE recommends Astellas' Veoza for NHS use.
Veoza treats moderate to severe vasomotor symptoms associated with menopause.
The recommendation opens a new market for Veoza in the UK's public healthcare system.
Astellas Pharma (Japan) can leverage Veoza's UK success to inform APAC market strategies. Aging populations in Japan, South Korea, and Australia present significant demand for non-hormonal menopause treatments. APAC competitors will monitor Veoza's uptake, potentially influencing their R&D. Regional regulators may also consider NICE's assessment as a benchmark.
Veoza treats moderate to severe vasomotor symptoms associated with menopause.
The recommendation opens a new market for Veoza in the UK's public healthcare system.
Sign in to save notes on signals.
Sign In